An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)(D-TA):

##STR00001##

in which p represents an integer of 0 to 4; R.sup.1 each independently represent a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group, a cyanated C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkoxy group, a C.sub.1-6 alkoxy C.sub.1-6 alkyl group, a mono-/di-C.sub.2-7 alkanoyl amino group, a carboxamide group, or a C.sub.1-6 alkoxy carbonyl group; and R.sup.2a and R.sup.2b each independently represent a C.sub.1-6 alkyl group.

An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)(D-TA):

##STR00001##

in which p represents an integer of 0 to 4; R.sup.1 each independently represent a halogen atom, a cyano group, a C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group, a cyanated C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkoxy group, a C.sub.1-6 alkoxy C.sub.1-6 alkyl group, a mono-/di-C.sub.2-7 alkanoyl amino group, a carboxamide group, or a C.sub.1-6 alkoxy carbonyl group; and R.sup.2a and R.sup.2b each independently represent a C.sub.1-6 alkyl group.

Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection, in particular analgesics such as buprenorphine.

Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection, in particular analgesics such as buprenorphine.

Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.

Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

There are described ROR modulators of the formula (I), ##STR00001##
and formula (II) ##STR00002##
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR activity, for example, autoimmune and/or inflammatory disorders.

This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.